4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS 327-78-6 Purity ≥99.0% Sorafenib Tosylate Intermediate Factory
Commercial Supply Sorafenib Tosylate and Related Intermediates:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate (CAS: 327-78-6) with high quality, intermediate of Sorafenib Tosylate (CAS: 475207-59-1). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Sorafenib Tosylate Intermediates, Please contact: alvin@ruifuchem.com
Name | 4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate |
Synonyms | Isocyanic Acid 4-Chloro-3-(Trifluoromethyl)phenyl Ester; 4-Chloro-α,α,α-Trifluoro-m-Tolyl Isocyanate |
CAS Number | 327-78-6 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C8H3ClF3NO |
Molecular Weight | 221.56 |
Melting Point | 37.0~42.0℃ (lit.) |
Boiling Point | 86.0~90.0℃/14 mmHg (lit.) |
Flash Point | 99℃(210°F) |
Density | 1.4720 |
Sensitive | Moisture Sensitive, Heat Sensitive |
Storage Condition | Store Under Inert Gas (Nitrogen or Argon) at 2~8℃ |
Shipping Conditions | Ambient |
COA & MSDS | Available |
Place of Origin | Shanghai, China |
Brand | Ruifu Chemical |
Item | Specifications | Results |
Appearance | White Crystalline | White Crystalline |
Purity / Analysis Method | ≥99.0% (HPLC) | 99.74% |
Identification | (1) IR / (2) HPLC | Conforms |
Moisture (K.F) | ≤0.50% | 0.06% |
Residue on Ignition | ≤0.50% | 0.11% |
Heavy Metals | ≤10ppm | <10ppm |
Ordinary Impurities | ||
Impurity A | ≤0.15% | 0.00% |
Impurity B | ≤1.00% | 0.26% |
Impurity C | ≤1.00% | 0.00% |
Other Single Impurity | ≤0.50% | 0.26% |
Total Impurities | ≤1.00% | 0.26% |
Residual Solvent Toluene | ≤0.089% | 0.00% |
Conclusion | The product has been tested and complies with the given specifications | |
Application | Intermediate of Sorafenib Tosylate (CAS: 475207-59-1) |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Store keep far away from sunlight, sealed at a temperature below 25℃ and forbidden to contact alcohols organic solvent and water.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
Hazard Symbols Xn - Harmful
Risk Codes R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed.
R36/37 - Irritating to eyes and respiratory system.
R36/37/38 - Irritating to eyes, respiratory system and skin.
R42 - May cause sensitization by inhalation
R20/22 - Harmful by inhalation and if swallowed.
Safety Description S7 - Keep container tightly closed.
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S27 - Take off immediately all contaminated clothing.
S37/39 - Wear suitable gloves and eye/face protection
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S23 - Do not breathe vapour.
UN IDs UN 2206 6.1/PG 3
WGK Germany 3
HS Code 2929109000
Hazard Note Harmful / Moisture Sensitive
Hazard Class 6.1
Packing Group III
Sorafenib Tosylate (CAS: 475207-59-1) is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and HCC. Sorafenib Tosylate (CAS: 475207-59-1) can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.